Penatalaksanaan Hipertensi di Era Pandemi COVID-19

Bilah Samping Artikel

Diterbitkan Jul 12, 2022
https://doi.org/10.30651/ps.v1i1.13708
Download
PDF
Statistic
Vol 1 No 1 (2022): PROSIDING WEBINAR FAKULTAS KEDOKTERAN UNIVERSITAS MUHAMMADIYAH SURABAYA

Isi Artikel Utama

Irma Kartikasari
Fakultas Kedokteran Universitas Muhammadiyah Surabaya
Muhammad Afif
Profesi Kedokteran Universitas Muhammadiyah Surabaya

Abstrak

Abstract

Hypertension is the leading risk factor for adverse cardiovascular disease outcomes. Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic responsible for millions of deaths around the world. Hypertension has been identified as one of the most common comorbidities and risk factors for severity and adverse outcome in these patients. Concern has been expressed that treatment with ACEIs or ARBs might increase the risk of infection, or developing the severe consequences of infection with COVID-19. Numerous original studies and meta-analysis reported no relationship with severity or mortality in COVID-19 patients or even benefit of taking renin-angiotensin-aldosterone inhibitors in COVID-19 patients. The goal of the various hypertension guidelines is to provide easily accessible information to healthcare providers and public health officials, which is key for optimal clinical practice. However, the COVID-19 pandemic has challenged the ability to provide safe care to the most vulnerable hypertensive populations throughout the world. The aim of this review article is to provide an overview of the current evidence on hypertension management in Covid-19 pandemic era.

Keywords: Hypertension, COVID-19, Anti-Hypertensive Drugs, Cardiovascular Disease

Abstrak

Rincian Artikel

Referensi

  1. Daftar Pustaka
  2. Walker AJ, Williamson E, Bhaskaran K. (2020). OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.
  3. Peltzer K, Pengpid S. (2018). The Prevalence and Social Determinants of Hypertension among Adults in Indonesia: A Cross-Sectional Population-Based National Survey. International Journal of Hypertension, 5610725, 1-9.
  4. Saputra PBT, Izzati N, Rosita PE, et al. (2021). NATIONAL HEALTH INSURANCE-BASED TELEMEDICINE IMPLEMENTATION FOR HYPERTENSION MANAGEMENT IN PRIMARY CENTRES. Journal of Community Medicine and Public Health Research, 2 (1), 32 – 40.
  5. Clark CE, McDonagh STJ, McManus RJ, et al. (2021). COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. Journal of Human Hypertension, 35, 304–307.
  6. Eshak ES, Liu X, Mubarik S. (2021). The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. Frontiers in Medicine, 623608, 1-13.
  7. Enabling Delivery of Essential Health Services during the COVID 19 Outbreak: Guidance note.
  8. Daniele A, Elena A, Emanuele B. (2020). The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. COVID-19-Guidance, pg.1-119. (Last update: 10 June 2020).
  9. Driggin E, Maddox TM, Ferdinand KC, et al. (2021). ACC health policy statement on cardiovascular disease considerations for COVID-19 vaccine prioritization: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 77, 1938–48.
  10. Chen G, Gong Z, Li X, et al. (2020). Hypertension as a sequela in patients of SARS-CoV-2 infection. PLoS ONE, 16(4): e0250815.
  11. Arima H, Asayama K, Shibata S, et al. (2020). Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Springer Nature, 1-19.
  12. Ferdinand KC, Vo TN, Echols MR. (2020). State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. American Journal of Preventive Cardiology, 100038(2), 1-9.
  13. Horn DM, Mirsky JB. (2020). Chronic Disease Management in the COVID-19 Era. The American Journal of Managed Care, 26(8), 329-330.
  14. Grassi G, Saeed S, Tadic M. (2021). Hypertension and COVID-19: Ongoing Controversies. Frontiers Cardiovascular Medicine, 8:639222.
  15. Feolaa M, Palazzuoli A, Ruoccoa G. (2020). Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases, 95, 373–375.
  16. Skeete J, Connell K, Ordunez P. (2020). Approaches to the Management of Hypertension in Resource-Limited Settings: Strategies to Overcome the Hypertension Crisis in the Post-COVID Era. Integrated Blood Pressure Control, 13, 125–133.